Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ilene Ceil Weitz. (2023) Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. Journal of Blood Medicine 14, pages 239-245.
Read now
Read now
Woojun Kim & Ho Jin Kim. (2023) An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Review of Clinical Immunology 19:1, pages 111-121.
Read now
Read now
Sung-Eun Lee & Jong Wook Lee. (2021) Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opinion on Drug Safety 20:2, pages 171-179.
Read now
Read now
Articles from other publishers (10)
Kensuke Usuki, Takayuki Ikezoe, Ken Ishiyama, Yoshinobu Kanda, Akihiko Gotoh, Hideo Hayashi, Akihiko Shimono, Akiyo Kitajima, Naoshi Obara & Jun-ichi Nishimura. (2023) Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan. International Journal of Hematology 118:3, pages 311-322.
Crossref
Crossref
Alicia Rovó, Mathilde Gavillet, Beatrice Drexler, Peter Keller, Jenny Sarah Schneider, Giuseppe Colucci, Yan Beauverd, Hendrika Anette van Dorland, Matthias Pollak, Adrian Schmidt, Andrea De Gottardi, Marina Bissig, Thomas Lehmann, Michel A. Duchosal & Sacha Zeerleder. (2023) Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones. Frontiers in Medicine 10.
Crossref
Crossref
Woojun Kim. (2023) Monoclonal Antibody Therapies for Neuromyelitis Optica Spectrum Disorder. Journal of Multiple Sclerosis and Neuroimmunology 14:1, pages 15-23.
Crossref
Crossref
Manaswini Ghosh & Soumendra Rana. (2023) The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics. International Immunopharmacology 118, pages 110081.
Crossref
Crossref
Austin G. Kulasekararaj, David J. Kuter, Morag Griffin, Ilene C. Weitz & Alexander Röth. (2023) Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Reviews 59, pages 101041.
Crossref
Crossref
Jin Seok Kim, Jun Ho Jang, Deog-Yeon Jo, Seo-Yeon Ahn, Sung-Soo Yoon, Je-Hwan Lee, Sung-Hyun Kim, Chul Won Choi, Ho-Jin Shin, Min-Kyoung Kim, Jae Hoon Lee, Yeung-Chul Mun, Jee Hyun Kong, BokJin Hyun, HyunSun Nam, Eunhye Kim, Min Joo Kwak, Yong Kyun Won & Jong Wook Lee. (2023) Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea. Journal of Korean Medical Science 38.
Crossref
Crossref
Jun-ichi Nishimura, Kiyoshi Ando, Masayoshi Masuko, Hideyoshi Noji, Yoshikazu Ito, Jiri Mayer, Laimonas Griskevicius, Christoph Bucher, Florian Müllershausen, Peter Gergely, Izabela Rozenberg, Anna Schubart, Raghav Chawla, Jean-Michel Rondeau, Michael Roguska, Igor Splawski, Mark T. Keating, Leslie Johnson, Rambabu Danekula, Morten Bagger, Yoko Watanabe, Börje Haraldsson & Yuzuru Kanakura. (2022) Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica 107:6, pages 1483-1488.
Crossref
Crossref
Helen Doll, Ufuk Coşkun, Chris Hartford & Ioannis Tomazos. (2021) Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria. Journal of Patient-Reported Outcomes 5:1.
Crossref
Crossref
Jonathan Barratt & Ilene Weitz. (2021) Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Frontiers in Immunology 12.
Crossref
Crossref
Peter Garred, Andrea J. Tenner & Tom E. Mollnes. (2021) Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacological Reviews 73:2, pages 792-827.
Crossref
Crossref